These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 12182145)

  • 1. HAART breaks: structured treatment interruptions.
    Grinberg L
    Focus; 2000 Sep; 15(10):5-6. PubMed ID: 12182145
    [No Abstract]   [Full Text] [Related]  

  • 2. Structured interruptions of therapy: looking for the best protocol.
    Aiuti F; Giovannetti A
    AIDS; 2003 Oct; 17(15):2257-8. PubMed ID: 14523284
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting differential responses to structured treatment interruptions during HAART.
    Bajaria SH; Webb G; Kirschner DE
    Bull Math Biol; 2004 Sep; 66(5):1093-118. PubMed ID: 15294419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics and evolution of HIV-1 during structured treatment interruptions.
    Frost SD
    AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre.
    Schrooten W; Florence E; Dreezen C; Van Esbroeck M; Fransen K; Alonso A; Desmet P; Colebunders R; Kestens L; De Roo A
    Int J STD AIDS; 2004 Aug; 15(8):523-8. PubMed ID: 15307962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structured treatment interruptions: a risky business.
    Montaner J; Harris M; Hogg R
    Clin Infect Dis; 2005 Feb; 40(4):601-3. PubMed ID: 15712084
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic hepatitis C in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2002; 56 Suppl 5():41-5. PubMed ID: 15553071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Structured interruptions in antiretroviral treatment: a new therapeutic strategy?].
    García F
    Enferm Infecc Microbiol Clin; 2002 Oct; 20(8):373-5. PubMed ID: 12372231
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.
    Burgoyne RW; Tan DH
    J Antimicrob Chemother; 2008 Mar; 61(3):469-73. PubMed ID: 18174196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Starting highly active antiretroviral therapy: why, when and response to HAART.
    Mocroft A; Lundgren JD
    J Antimicrob Chemother; 2004 Jul; 54(1):10-3. PubMed ID: 15163656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.